Celiac Disease Treatment Report 2025: For Strategy Officers and Market Intelligence Teams

June 16, 2025 12:23 PM BST | By EIN Presswire
 Celiac Disease Treatment Report 2025: For Strategy Officers and Market Intelligence Teams
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 16, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

What Does The Data On The Celiac Disease Treatment Market Size Indicate?
The Business Research Company’s latest report explores the dynamic growth of the global celiac disease treatment market. Underpinned by a series of recent socio-economic and health-augmenting trends, the market witnessed a steady surge in its value, growing from a size of $0.61 billion in 2024 to an estimated value of $0.67 billion in 2025. This equates to a commendable compound annual growth rate CAGR of 9.9%.

What Is Driving The Emerging Trend Of Celiac Disease Treatment On The Global Scale?
An array of driving forces can be attributed to the aforementioned growth in the celiac treatment market. The surge in the prevalence of celiac disease coupled with an amplified awareness and diagnosis rates spearheads these trends. Other dominant factors laying the growth track include the rising demand for non-dietary treatment options, a robust pipeline of novel therapies, supportive regulatory initiatives, and an increase in investment from leading pharmaceutical companies.

Going ahead, the market is expected to further broaden its horizon, projected to reach a sizable height of $0.96 billion in 2029, depicting an impressive CAGR of 9.6%. The forecast period could observe a transition fueled by the increasing global prevalence of celiac disease, enhancements in diagnosis rates, and rising clinical trials for new-generation treatments. The pursuit of gluten-free alternatives, supportive initiatives for orphan diseases, and surging healthcare expenditure also provide strategic avenues for growth.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24186&type=smp

Who Are Key Stakeholders Steering The Celiac Disease Treatment Market's Course?
The key stakeholders shaping the landscape of the celiac disease treatment market include Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceuticals Company Ltd., Amgen Inc., General Mills Inc., Viatris Inc., Teva Pharmaceutical Inc., Nestlé Health Science, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals Inc., Glenmark Pharmaceuticals Company Ltd., West-Ward Pharmaceuticals Company Ltd, Innovate Biopharmaceutical, Acto Biosciences, ImmunogenX.

How Are The Celiac Disease Treatment Market Trends Being Transformed By Key Players To Drive Growth?
A striking trend of shifting focus on developing oral therapies such as small molecule therapies to block the immunity response to gluten is being observed. By improving patient adherence and offering alternatives to strict gluten-free diets, companies aim to deliver targeted relief and broaden their market impact. One such remarkable example is of Immunic Inc., a US-based biotechnology company, that launched IMU-856 in February 2025, a small molecule that enhances intestinal barrier function, nutrient absorption, and alleviates symptoms without suppressing immune activity.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/celiac-disease-treatment-global-market-report

How Is The Celiac Disease Treatment Market Segmented?
The global celiac disease treatment market structures itself into several intriguing segments and sub-segments:

Treatment Type-wise, the market is divided into categories such as Vitamins And Minerals, Gluten Degrading Enzymes, Symptomatic Treatment, and Other Treatments.
Further segmenting by Enzyme Type, categories include Distension, Diarrhoea, Anorexia, Bloating, Gas, Fatigue.

In terms of Diagnosis, it includes Serological Tests, Genetic Testing, Biopsy.
Based on Distribution Channel, Hospitals, Research Centres, Clinics, and Other Distribution Channels comprise the variety.

What Regional Insights Impact The Celiac Disease Treatment Market Logistics?
On a regional front, North America emerged as the largest market region in 2024. However, the Asia-Pacific region is expected to be the fastest-growing region in the coming period. Other regions covering the market include Western Europe, Eastern Europe, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Immune Health Supplements Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report

Veterinary Infectious Disease Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/veterinary-infectious-disease-diagnostics-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

About The Business Research Company
Learn more about The Business Research Company. With a powerhouse of over 15000+ reports from 27 industries spanning 60+ geographies, The Business Research Company has set a benchmark in providing comprehensive, data-rich research intelligence. Equipped with 1,500,000 datasets, persistent in-depth secondary research, and exclusive insights from industry wizards, we ensure you stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next